Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gassler N, Drescher R, Freesmeyer M, Malouhi A, Buerckenmeyer F, Aschenbach R, Teichgraeber U, Koegler C, Vogt M, Hofmann GO, Hochhaus A (2022)
Publication Type: Journal article
Publication year: 2022
Journal
DOI: 10.1007/s00432-022-04496-y
Abstract
With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.
Authors with CRIS profile
Abbas Agaimy
Medizinische Fakultät
Robert Stöhr
Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie
Arndt Hartmann
Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie
Involved external institutions
Germany (DE)How to cite
APA:
Schrenk, K.G., Weschenfelder, W., Spiegel, C., Agaimy, A., Stöhr, R., Hartmann, A.,... Hochhaus, A. (2022). Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-022-04496-y
MLA:
Schrenk, Karin G., et al. "Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma." Journal of Cancer Research and Clinical Oncology (2022).
BibTeX: Download